Search Result
Results for "
BMPS
" in MedChemExpress (MCE) Product Catalog:
3
Biochemical Assay Reagents
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-42146
-
|
|
ADC Linker
|
Cancer
|
|
BMPS is a nonclaevable ADC linker used in the synthesis of antibody-drug conjugates (ADCs).
|
-
-
- HY-124697
-
|
|
TGF-β Receptor
|
Cancer
|
|
BMP signaling agonist sb4 is a potent benzoxazole bone morphogenetic protein 4 (BMP4) signaling agonist with a EC50 value of 74 nM, activates BMP signaling by stabilizing intracellular p-SMAD-1/5/9. BMP signaling agonist sb4 activates BMP4 target genes (inhibitors of DNA binding,?Id1?and?Id3) canonical BMP signaling .
|
-
-
- HY-143891
-
|
|
TGF-β Receptor
|
Others
|
|
Chromenone 1 is a potent osteogenic bone morphogenetic protein (BMP) potentiator. Chromenone 1 exhibits a unique mode of action as it induces a pronounced, kinase-independent, negative TGFβ feedback that enhances nuclear BMP-Smad signaling outputs .
|
-
-
- HY-147372
-
|
|
TGF-beta/Smad
|
Metabolic Disease
|
|
SJ000063181 is a potent BMP signaling activator with an EC50 ≤1 µM. SJ000063181 can be used as chemical probes to interrogate BMP signaling due to it can penetrate zebrafish embryos .
|
-
-
- HY-164145
-
|
|
TGF-β Receptor
|
Others
Cancer
|
|
CDD-1653 is a potent and selective BMPR2 inhibitor (IC50=2.8 nM). CDD-1653 reduces the ability of ATP to bind to the kinase domain of BMPR2, thereby affecting the phosphorylation of SMAD1/5/8 transcription factors, which play a key role in the BMP signaling pathway. CDD-1653 can be used to study diseases related to the BMP signaling pathway .
|
-
-
- HY-N4019
-
|
|
TGF-β Receptor
|
Metabolic Disease
|
|
Maohuoside A, a single compound isolated from the E. koreanum that potently promotes osteogenesis. Maohuoside A enhances the osteogenesis of bone marrow-derived mesenchymal stem cells via bone morphogenetic protein (BMP) and MAPK signaling pathways .
|
-
-
- HY-123900
-
-
-
- HY-12071
-
|
DM-3189
|
Organoid
TGF-β Receptor
|
Cancer
|
|
LDN193189 is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .
|
-
-
- HY-155705
-
|
|
TGF-β Receptor
GSK-3
β-catenin
|
Others
|
|
BMP agonist 1 (compound 2 b) is a small-molecule agonist of bone morphogenic protein (BMP). BMP induces C2C12 cell differentiation with BMP and highly depends on active BMP signaling. BMP agonist 1 inhibits GSK3β, increases β-catenin signaling and synergistically regulates Id2and Id3 expression. BMP agonist 1 is used in diseases and defects of the skeleton research .
|
-
-
- HY-171248
-
|
|
Anaplastic lymphoma kinase (ALK)
|
Cardiovascular Disease
Endocrinology
|
|
CDD-1115 is a potent, selective inhibitor of BMPR2 with IC50 of 1.8 nM, Kiapp of 6.2 nM. CDD-1115 inhibits bone morphogenetic protein (BMP)-mediated gene expression. BMP controls cellular processes across many tissue types, including the kidney, skeletal muscle, heart, and reproductive organs. BMP induces ectopic bone formation .
|
-
-
- HY-13418A
-
Dorsomorphin
Maximum Cited Publications
618 Publications Verification
Compound C; BML-275
|
Organoid
AMPK
TGF-β Receptor
Autophagy
|
Cancer
|
|
Dorsomorphin (Compound C) is a selective and ATP-competitive AMPK inhibitor (Ki=109 nM in the absence of AMP). Dorsomorphin (BML-275) selectively inhibits BMP type I receptors ALK2, ALK3, and ALK6. Dorsomorphin can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599) .
|
-
-
- HY-108531
-
|
|
RAR/RXR
|
Cancer
|
|
ER-50891 is a potent antagonist of retinoic acid receptor α(RARα). ER-50891 significantly attenuates ATRA's inhibitive effects on BMP 2-induced osteoblastogenesis .
|
-
-
- HY-108531A
-
|
|
RAR/RXR
|
Cancer
|
|
ER 50891 quarterhydrate is a potent antagonist of retinoic acid receptor α(RARα). ER 50891 quarterhydrate significantly attenuates ATRA's inhibitive effects on BMP 2-induced osteoblastogenesis .
|
-
-
- HY-13418
-
|
Compound C dihydrochloride; BML-275 dihydrochloride
|
Organoid
AMPK
TGF-β Receptor
Autophagy
|
Cancer
|
|
Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).
|
-
-
- HY-174416
-
|
|
E1/E2/E3 Enzyme
|
Cardiovascular Disease
|
|
Smurf1-IN-5 (Compound cpd-6) is an allosteric SMAD ubiquitin regulatory factor 1 (SMURF1) inhibitor. Smurf1-IN-5 leads to a reduction in the ubiquitylation of substrates such as BMPR2 (bone morphogenetic protein receptor 2) and SMAD1, enhancing the BMP (bone morphogenetic protein) signaling pathway. Smurf1-IN-5 is promising for research of pulmonary arterial hypertension (PAH) .
|
-
-
- HY-150793
-
-
-
- HY-13418R
-
|
|
Organoid
AMPK
TGF-β Receptor
Autophagy
|
Cancer
|
|
Dorsomorphin (dihydrochloride) (Standard) is the analytical standard of Dorsomorphin (dihydrochloride). This product is intended for research and analytical applications. Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).
|
-
-
- HY-P99359
-
|
ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody (elezanumab)
|
TGF-beta/Smad
|
Metabolic Disease
|
|
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism .
|
-
-
- HY-150795
-
|
|
TGF-beta/Smad
PI3K
Akt
ERK
JNK
|
Others
|
|
SY-LB-35 is a potent bone morphogenetic protein (BMP) receptor agonist. SY-LB-35 can stimulate significant increases in cell number and cell viability in the C2C12 myoblast cell line, and causes shifts towards the S and G2/M phases of the cell cycle. SY-LB-35 stimulates canonical Smad and non-canonical PI3K/Akt, ERK, p38 and JNK intracellular signaling pathways .
|
-
-
- HY-P99643
-
|
UCB6114
|
Dan family
|
Cancer
|
|
Ginisortamab (UCB6114) is a fully human IgG4P anti Gremlin-1 monoclonal antibody, with mean IC50 values of 8.2 nM and 9 nM against human and mouse gremlin-1, respectivly. Ginisortamab inhibits gremlin-1 antagonism of BMP signaling pathways. Ginisortamab has the potential for the research of gastrointestinal (GI) tumors .
|
-
-
- HY-N0123
-
|
Barbaloin-A
|
Wnt
|
Cancer
|
|
Aloin (Aloin-A; Barbaloin-A) is a natural anti-tumor anthraquinone glycoside with iron chelating activity. Aloin induces the differentiation of MC3T3-E1 cells into osteoblasts through MAPK-mediated Wnt and Bmp signaling pathways. Alkaline phosphatase (ALP) is an early marker of osteoblast differentiation, and the activity of ALP is also enhanced by Aloin. Aloin also reduces brain edema, reduces blood-brain barrier disruption and improves cortical impact injuries. Aloin is used in research into osteoporosis and traumatic brain injury (TBI) .
|
-
-
- HY-158203
-
|
|
TGF-β Receptor
|
Others
|
|
BMP agonist 2 (derivative I-9) is a potent bone-inducing cytokine. BMP agonist 2 promotes bone tissue production by increasing the proportion and activity of osteoblasts. BMP agonist 2 promotes osteoblast proliferation and differentiation through the BMP2-ATF4 signaling axis, in which ATF4 is a transcription factor closely related to osteoblast differentiation and bone formation. BMP agonist 2 can be used in the study of senile osteoporosis (SOP) .
|
-
-
- HY-N0123R
-
|
Barbaloin-A (Standard)
|
Reference Standards
Wnt
|
Cancer
|
|
Aloin (Standard) is the analytical standard of Aloin. This product is intended for research and analytical applications. Aloin (Aloin-A; Barbaloin-A) is a natural anti-tumor anthraquinone glycoside with iron chelating activity. Aloin induces the differentiation of MC3T3-E1 cells into osteoblasts through MAPK-mediated Wnt and Bmp signaling pathways. Alkaline phosphatase (ALP) is an early marker of osteoblast differentiation, and the activity of ALP is also enhanced by Aloin. Aloin also reduces brain edema, reduces blood-brain barrier disruption and improves cortical impact injuries. Aloin is used in research into osteoporosis and traumatic brain injury (TBI) .
|
-
-
- HY-P990974
-
-
-
- HY-15897
-
|
|
TGF-β Receptor
|
Cancer
|
|
LDN-212854 is a bone morphogenetic protein (BMP) inhibitor that potently inhibits ALK2 (IC50: 1.3 nM). LDN-212854 also inhibits ALK1 (IC50: 2.40 nM). LDN-212854 can be used in the research of fibrodysplasia ossificans progressive and cancers, such as hepatocellular carcinoma (HCC) .
|
-
-
- HY-12071G
-
|
DM-3189
|
TGF-β Receptor
|
Cancer
|
|
LDN193189 (DM-3189) (GMP) is LDN193189 (HY-12071) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. LDN193189 is selective BMP type I receptor inhibitor .
|
-
-
- HY-P10710
-
|
|
IFNAR
Interleukin Related
COX
|
Inflammation/Immunology
|
|
BMP-4 is a penetrating heparin-binding peptide with anti-inflammatory and anti-chondrogenic functions. In murine chondrocytes and macrophages, BMP-4 regulates the iNOS-IFN-IL6 signaling pathway to inhibit the expression of inflammatory proteins such as iNOS, COX2, IFN, and IL6 in a dose-dependent manner, effectively suppressing inflammation and alleviating various arthritis symptoms .
|
-
-
- HY-N8920
-
|
|
Others
|
Metabolic Disease
|
|
Syringetin, a flavonoid derivative, is associated with increased BMP-2 production. Syringetin stimulates osteoblast differentiation at various stages, from maturation to terminally differentiated osteoblasts .
|
-
-
- HY-112331
-
|
|
TGF-β Receptor
|
Cancer
|
|
SJ000291942 is an activator of the canonical bone morphogenetic proteins (BMP) signaling pathway. BMPs are members of the transforming growth factor beta (TGFβ) family of secreted signaling molecules.
|
-
-
- HY-RS01533
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
BMP1 Human Pre-designed siRNA Set A contains three designed siRNAs for BMP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
BMP1 Human Pre-designed siRNA Set A
BMP1 Human Pre-designed siRNA Set A
-
- HY-RS28931
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Bmp8a Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmp8a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Bmp8a Rat Pre-designed siRNA Set A
Bmp8a Rat Pre-designed siRNA Set A
-
- HY-RS24417
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Bmp6 Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmp6 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Bmp6 Rat Pre-designed siRNA Set A
Bmp6 Rat Pre-designed siRNA Set A
-
- HY-RS25609
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Bmp5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmp5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Bmp5 Rat Pre-designed siRNA Set A
Bmp5 Rat Pre-designed siRNA Set A
-
- HY-RS17049
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Bmp7 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmp7 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Bmp7 Mouse Pre-designed siRNA Set A
Bmp7 Mouse Pre-designed siRNA Set A
-
- HY-RS23493
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Bmp7 Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmp7 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Bmp7 Rat Pre-designed siRNA Set A
Bmp7 Rat Pre-designed siRNA Set A
-
- HY-RS01535
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
BMP15 Human Pre-designed siRNA Set A contains three designed siRNAs for BMP15 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
BMP15 Human Pre-designed siRNA Set A
BMP15 Human Pre-designed siRNA Set A
-
- HY-RS17946
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Bmp6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmp6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Bmp6 Mouse Pre-designed siRNA Set A
Bmp6 Mouse Pre-designed siRNA Set A
-
- HY-RS19176
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Bmp15 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmp15 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Bmp15 Mouse Pre-designed siRNA Set A
Bmp15 Mouse Pre-designed siRNA Set A
-
- HY-RS01539
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
BMP4 Human Pre-designed siRNA Set A contains three designed siRNAs for BMP4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
BMP4 Human Pre-designed siRNA Set A
BMP4 Human Pre-designed siRNA Set A
-
- HY-RS20696
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Bmp3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmp3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Bmp3 Mouse Pre-designed siRNA Set A
Bmp3 Mouse Pre-designed siRNA Set A
-
- HY-RS23061
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Bmp2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmp2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Bmp2 Rat Pre-designed siRNA Set A
Bmp2 Rat Pre-designed siRNA Set A
-
- HY-RS25665
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Bmp15 Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmp15 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Bmp15 Rat Pre-designed siRNA Set A
Bmp15 Rat Pre-designed siRNA Set A
-
- HY-RS16511
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Bmp4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmp4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Bmp4 Mouse Pre-designed siRNA Set A
Bmp4 Mouse Pre-designed siRNA Set A
-
- HY-RS19175
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Bmp10 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmp10 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Bmp10 Mouse Pre-designed siRNA Set A
Bmp10 Mouse Pre-designed siRNA Set A
-
- HY-RS01536
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
BMP2 Human Pre-designed siRNA Set A contains three designed siRNAs for BMP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
BMP2 Human Pre-designed siRNA Set A
BMP2 Human Pre-designed siRNA Set A
-
- HY-RS01538
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
BMP3 Human Pre-designed siRNA Set A contains three designed siRNAs for BMP3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
BMP3 Human Pre-designed siRNA Set A
BMP3 Human Pre-designed siRNA Set A
-
- HY-RS24817
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Bmp1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmp1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Bmp1 Rat Pre-designed siRNA Set A
Bmp1 Rat Pre-designed siRNA Set A
-
- HY-RS01543
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
BMP8A Human Pre-designed siRNA Set A contains three designed siRNAs for BMP8A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
BMP8A Human Pre-designed siRNA Set A
BMP8A Human Pre-designed siRNA Set A
-
- HY-RS16626
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Bmp2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmp2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Bmp2 Mouse Pre-designed siRNA Set A
Bmp2 Mouse Pre-designed siRNA Set A
-
- HY-RS01541
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
BMP6 Human Pre-designed siRNA Set A contains three designed siRNAs for BMP6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
BMP6 Human Pre-designed siRNA Set A
BMP6 Human Pre-designed siRNA Set A
- HY-RS01542
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
BMP7 Human Pre-designed siRNA Set A contains three designed siRNAs for BMP7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
BMP7 Human Pre-designed siRNA Set A
BMP7 Human Pre-designed siRNA Set A
- HY-RS19119
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Bmp5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmp5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Bmp5 Mouse Pre-designed siRNA Set A
Bmp5 Mouse Pre-designed siRNA Set A
- HY-RS22407
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Bmp8a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmp8a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Bmp8a Mouse Pre-designed siRNA Set A
Bmp8a Mouse Pre-designed siRNA Set A
- HY-RS22943
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Bmp4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmp4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Bmp4 Rat Pre-designed siRNA Set A
Bmp4 Rat Pre-designed siRNA Set A
- HY-RS27207
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Bmp3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmp3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Bmp3 Rat Pre-designed siRNA Set A
Bmp3 Rat Pre-designed siRNA Set A
- HY-RS01540
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
BMP5 Human Pre-designed siRNA Set A contains three designed siRNAs for BMP5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
BMP5 Human Pre-designed siRNA Set A
BMP5 Human Pre-designed siRNA Set A
- HY-RS25664
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Bmp10 Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmp10 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Bmp10 Rat Pre-designed siRNA Set A
Bmp10 Rat Pre-designed siRNA Set A
- HY-RS01534
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
BMP10 Human Pre-designed siRNA Set A contains three designed siRNAs for BMP10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
BMP10 Human Pre-designed siRNA Set A
BMP10 Human Pre-designed siRNA Set A
- HY-RS18338
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Bmp1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmp1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Bmp1 Mouse Pre-designed siRNA Set A
Bmp1 Mouse Pre-designed siRNA Set A
- HY-RS17130
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Bmp2k Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmp2k gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Bmp2k Mouse Pre-designed siRNA Set A
Bmp2k Mouse Pre-designed siRNA Set A
- HY-RS01537
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
BMP2K Human Pre-designed siRNA Set A contains three designed siRNAs for BMP2K gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
BMP2K Human Pre-designed siRNA Set A
BMP2K Human Pre-designed siRNA Set A
- HY-RS27380
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Bmp8b Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmp8b gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Bmp8b Rat Pre-designed siRNA Set A
Bmp8b Rat Pre-designed siRNA Set A
- HY-RS01544
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
BMP8B Human Pre-designed siRNA Set A contains three designed siRNAs for BMP8B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
BMP8B Human Pre-designed siRNA Set A
BMP8B Human Pre-designed siRNA Set A
- HY-RS20865
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Bmp8b Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmp8b gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Bmp8b Mouse Pre-designed siRNA Set A
Bmp8b Mouse Pre-designed siRNA Set A
- HY-RS23575
-
|
|
Small Interfering RNA (siRNA)
|
Others
|
|
Bmp2k Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmp2k gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
Bmp2k Rat Pre-designed siRNA Set A
Bmp2k Rat Pre-designed siRNA Set A
- HY-N2682B
-
-
- HY-12071B
-
|
DM-3189 dihydrochloride
|
TGF-β Receptor
Organoid
|
Cancer
|
|
LDN-193189 (dihydrochloride) is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .
|
-
- HY-18961
-
-
- HY-121025
-
|
|
TGF-β Receptor
|
Others
|
|
BUR1 is a BMP upregulator (EC50: 98 nM) and activates BMPRII signalling. BUR1 induces BMP2 and PTGS2 expression. BUR1 reversed pulmonary arterial pressure in Monocrotaline (HY-N0750) induced rats .
|
-
- HY-P5157
-
|
|
Potassium Channel
|
Neurological Disease
|
|
BmP02 is a selective Kv1.3 channel blocker and a highly-selective Kv4.2 modulator, which can be isolated from Chinese scorpion (Buthus martensi Karsch) venom. BmP02 also delays the inactivation of Kv4.2 in HEK293T cells, with an EC50 value of ~850 nM. BmP02 inhibits the transient outward potassium currents (Ito) in ventricular muscle cells .
|
-
- HY-167580
-
-
- HY-12071BR
-
|
|
TGF-β Receptor
Organoid
|
Cancer
|
|
LDN-193189 (dihydrochloride) (Standard) is the analytical standard of LDN-193189 (dihydrochloride). This product is intended for research and analytical applications. LDN-193189 (dihydrochloride) is a potent selective BMP type I receptor (BMP I) inhibitor. LDN-193189 efficiently inhibits transcriptional activity of the BMP type I receptors ALK2 and ALK3 with IC50 values of 5 nM and 30 nM, respectively. LDN-193189 can be used for the research of bone morphogenetic protein signalling, such as fibrodysplasia ossificans progressiva .
|
-
- HY-13102
-
|
|
Procollagen C Proteinase
|
Others
|
|
UK-383367 is an orally available pro-collagen C-protease inhibitor (BMP-1) with an IC50 value of 44 nM. UK-383367 can reduce renal fibrosis and inflammation in chronic kidney disease (CKD) and may be used to study postoperative skin scarring .
|
-
- HY-135871
-
|
|
AAK1
|
Neurological Disease
|
|
BMT-124110 is a potent, selective AAK1 inhibitor with an IC50 of 0.9 nM. BMT-124110 shows antinociceptive activity. BMT-090605 inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC50s of 17 and 99 nM, respectively .
|
-
- HY-135871A
-
|
|
AAK1
|
Neurological Disease
|
|
BMT-124110 formic is a potent, selective AAK1 inhibitor, with an IC50 of 0.9 nM. BMT-124110 shows antinociceptive activity. BMT-124110 formic inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC50s of 17 and 99 nM, respectively .
|
-
- HY-171249
-
|
|
TGF-β Receptor
|
Cardiovascular Disease
Endocrinology
|
|
CDD-1431 is a low-nanomolar selective kinase inhibitors of BMPR2, with Kiapp value of 20.6 nM. CDD-1431 suppresses BRE-reporter activity, with an IC50 of 4.87 μM. BMP controls cellular processes across many tissue types, including the kidney, skeletal muscle, heart, and reproductive organs. BMP induces ectopic bone formation .
|
-
- HY-107245
-
|
|
Estrogen Receptor/ERR
Sirtuin
RUNX
|
Metabolic Disease
|
|
Segetalin B, an orally active cyclopentapeptide found in Vaccaria segetalis, possesses estrogen-like activity. Segetalin B promotes mineralization of ovariectomized rat-derived bone marrow mesenchymal stem cells (BMSCs) in vitro and increases the level of osteocalcin, BMP-2, ALP, and SIRT1 activity. Segetalin B is promising for research of post-menopausal osteoporosis (PMOP) .
|
-
- HY-N8261
-
|
|
Bacterial
TGF-beta/Smad
|
Infection
|
|
Amicoumacin B can be produced by actinomycete, strain 04-5195 T.. Amicoumacin B increases the expression of bone morphogenetic protein 2 (BMP-2). Amicoumacin B has inhibitory effect against C. violaceum (MIC = 250 µg/mL). Amicoumacin B has quorum sensing inhibitory activity, and reduces the expression of the C. violaceum operons vioA, vioB, vioD, and vioE, but increases the expression of vioC .
|
-
- HY-N2375
-
|
|
Wnt
β-catenin
p38 MAPK
|
Metabolic Disease
|
|
L-Quebrachitol is a methoxy analog of inositol that can be isolated from plants. L-Quebrachitol has free-radical scavenging, gastroprotection, anti-platelet aggregation and anti-diabetic activity. L-Quebrachitol promotes osteoblastogenesis by uppregulation of BMP-2, runt-related transcription factor-2 (Runx2), MAPK (ERK, JNK, p38α), and Wnt/β-catenin signaling pathway .
|
-
- HY-101290A
-
|
|
Cyclin G-associated Kinase (GAK)
AAK1
|
Neurological Disease
|
|
BMT-090605 hydrochloride is a potent, selective the adapter protein-2 associated kinase 1 (AAK1) inhibitor with an IC50 value of 0.6 nM. BMT-090605 hydrochloride shows antinociceptive activity. BMT-090605 hydrochloride inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC50 values of 45 nM and 60 nM, respectively. BMT-090605 hydrochloride can be used for the research of neuropathic pain .
|
-
- HY-101290
-
|
|
AAK1
Cyclin G-associated Kinase (GAK)
|
Neurological Disease
|
|
BMT-090605 is a potent, selective the adapter protein-2 associated kinase 1 (AAK1) inhibitor with an IC50 value of 0.6 nM. BMT-090605 shows antinociceptive activity. BMT-090605 inhibits BMP-2-inducible protein kinase (BIKE) and Cyclin G-associated kinase (GAK) with IC50 values of 45 nM and 60 nM, respectively. BMT-090605 can be used for the research of neuropathic pain .
|
-
- HY-N0265
-
-
- HY-16712
-
|
|
TGF-β Receptor
|
Cancer
|
|
LDN-214117 is an orally active ALK2 inhibitor with well-tolerated and good brain penetration. LDN-214117 has a high selectivity and low cytotoxicity for ALK2 with an IC50 value of 24 nM. LDN-214117 also is a specific bone morphogenetic proteins (BMPs) signaling inhibitor and has relatively selective inhibition for BMP6 with an IC50 value of 100 nM. LDN-214117 can be used for the research of fibrodysplasia ossificans progressiva (FOP), diffuse intrinsic pontine glioma (DIPG) .
|
-
- HY-120179A
-
|
|
AAK1
|
Neurological Disease
|
|
LP-922761 hydrate is a potent, selective and orally active adapter protein-2 associated kinase 1 (AAK1) inhibitor with IC50s of 4.8 nM and 7.6 nM in enzyme and cell assays, respectively. LP-922761 hydrate also inhibits BMP-2-inducible protein kinase (BIKE) with an IC50 of 24 nM. LP-922761 hydrate shows less activity at cyclin G-associated kinase (GAK), opioid, adrenergic α2 or GABAa receptors .
|
-
- HY-120179
-
|
|
AAK1
|
Neurological Disease
|
|
LP-922761 is a potent, selective and orally active adapter protein-2 associated kinase 1 (AAK1) inhibitor with IC50s of 4.8 nM and 7.6 nM in enzyme and cell assays, respectively. LP-922761 also inhibits BMP-2-inducible protein kinase (BIKE) with an IC50 of 24 nM. LP-922761 exhibits no significant activity at cyclin G-associated kinase (GAK), opioid, adrenergic α2 or GABAa receptors .
|
-
- HY-171247
-
|
|
TGF-β Receptor
|
Others
|
|
CDD-1281 is a highly potent and selective BMPR2 kinase inhibitor with an IC50 of 1.2 nM. CDD-1281 can effectively inhibit BMP-mediated gene expression .
|
-
- HY-110245
-
|
VU364849
|
Apoptosis
|
Cancer
|
|
DMH2 is a potent BMP receptor antagonist. DMH2 downregulates the expression of Id1 and Id3 proteins, and inhibits the proliferation and induces cell death of lung cancer cell lines .
|
-
- HY-10326
-
|
|
TGF-β Receptor
|
Cancer
|
|
GW788388 is a potent and selective inhibitor of ALK5 with IC50 of 18 nM, and also inhibits TGF-β type II receptor and activin type II receptor activities, without inhibiting BMP type II receptor.
|
-
- HY-N0265R
-
|
|
Reference Standards
Caspase
Apoptosis
PERK
Akt
p38 MAPK
HIF/HIF Prolyl-Hydroxylase
PPAR
|
Cardiovascular Disease
Neurological Disease
|
|
Asperosaponin VI (Standard) is the analytical standard of Asperosaponin VI. This product is intended for research and analytical applications. Asperosaponin VI is a saponin component from Dipsacus asper. Asperosaponin VI induces osteoblast differentiation through the BMP-2/p38 and ERK1/2 signaling pathways. Asperosaponin VI protects against hypoxia-induced cardiomyocyte apoptosis by activating the PI3K/Akt and CREB pathways. Additionally, Asperosaponin VI also has antidepressant and wound-healing-promoting activities .
|
-
- HY-N0316
-
|
|
JAK
NF-κB
Reactive Oxygen Species (ROS)
Apoptosis
VEGFR
c-Myc
|
Cancer
|
|
Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway .
|
-
- HY-12273
-
|
|
Autophagy
TGF-β Receptor
|
Cancer
|
|
DMH-1 is a potent and selective BMP inhibitor with IC50s of 27/107.9/<5/47.6 nM for ALK1/ALK2/ALK3/ALK6, respectively.
|
-
- HY-N0316R
-
|
|
JAK
Reference Standards
NF-κB
Reactive Oxygen Species (ROS)
Apoptosis
VEGFR
c-Myc
|
Cancer
|
|
Mollugin (Standard) is the analytical standard of Mollugin. This product is intended for research and analytical applications. Mollugin is an orally active and potent NF-κB inhibitor. Mollugin induces S-phase arrest of HepG2 cells, and increased intracellular reactive oxygen species (ROS) levels. Mollugin induces DNA damage in HepG2 cells, as well as an increase in the expression of p-H2AX. Mollugin shows anti-cancer effect by inhibiting TNF-α-induced NF-κB activation. Mollugin enhances the osteogenic action of BMP-2 (bone morphogenetic protein 2) via the p38-Smad signaling pathway .
|
-
- HY-12071A
-
|
DM-3189 Tetrahydrochloride
|
Organoid
TGF-β Receptor
|
Cancer
|
|
LDN193189 Tetrahydrochloride is a selective BMP type I receptor inhibitor, which efficiently inhibits ALK2 and ALK3 (IC50=5 nM and 30 nM, respectively), with weaker effects on ALK4, ALK5 and ALK7 (IC50≥500 nM) .
|
-
- HY-12273R
-
-
- HY-12278
-
K02288
3 Publications Verification
|
TGF-β Receptor
|
Others
|
|
K02288 is a potent bone morphogenetic protein (BMP) type I receptor inhibitor with IC50s of 1.8, 1.1, 6.4 nM for ALK1, ALK2 and ALK6, respectively. K02288 shows slightly weaker inhibition against ALK3 and ALK6 with IC50s of of 5-34 nM.
|
-
- HY-123940
-
|
|
Wnt
AAK1
|
Cancer
|
|
SGC-AAK1-1 is a potent and selective AAK1 (AP2 associated kinase 1) inhibitor with an IC50 of 270 nM and a Ki of 9 nM. SGC-AAK1-1 also potently inhibits BMP2K. SGC-AAK1-1 is used to study Wnt pathway related to AAK1 .
|
-
- HY-107818
-
|
|
NF-κB
|
Cardiovascular Disease
Inflammation/Immunology
|
|
4-Hydroxychalcone is a chalcone metabolite with anti-angiogenic and anti-inflammatory activities. 4-Hydroxychalcone suppresses angiogenesis by suppression of growth factor pathway with no signs of cytotoxicity . 4-Hydroxychalcone inhibits TNF-α induced NF-κB pathway activation and activates BMP signaling, reduces resistant hypertension (RH) by attenuating hyperaldosteronism and renal injury in mice .
|
-
- HY-12071AR
-
|
|
Organoid
TGF-β Receptor
|
Cancer
|
|
LDN193189 (Tetrahydrochloride) (Standard) is the analytical standard of LDN193189 (Tetrahydrochloride). This product is intended for research and analytical applications. LDN193189 Tetrahydrochloride is a selective BMP type I receptor inhibitor, which efficiently inhibits ALK2 and ALK3 (IC50=5 nM and 30 nM, respectively), with weaker effects on ALK4, ALK5 and ALK7 (IC50≥500 nM) .
|
-
- HY-12273G
-
|
|
TGF-β Receptor
Autophagy
|
Cancer
|
|
DMH-1 (GMP) is a GMP-grade version of DMH-1 (HY-12273). Small molecules of GMP grade can be used as adjuvant reagents in cell therapy. DMH-1 (GMP) promotes cardiac differentiation in mouse embryonic stem cells. DMH-1 (GMP) promotes neurogenesis of hiPSCs. DMH-1 is a potent and selective BMP inhibitor .
|
-
- HY-P0254A
-
|
|
Kisspeptin Receptor
|
Cardiovascular Disease
Cancer
|
|
Kisspeptin-10, human TFA is a potent vasoconstrictor and inhibitor of angiogenesis. Kisspeptin-10, human TFA acts as a tumor metastasis suppressor via its receptor GPR54. Kisspeptin-10-GPR54 system plays an important role in embryonic kidney development. Kisspeptin-10/GPR54 signaling induces osteoblast differentiation via NFATc4-mediated BMP2 expression .
|
-
- HY-P0254
-
|
|
Kisspeptin Receptor
|
Cardiovascular Disease
Cancer
|
|
Kisspeptin-10, human is a potent vasoconstrictor and inhibitor of angiogenesis. Kisspeptin-10, human acts as a tumor metastasis suppressor via its receptor GPR54. Kisspeptin-10-GPR54 system plays an important role in embryonic kidney development. Kisspeptin-10/GPR54 signaling induces osteoblast differentiation via NFATc4-mediated BMP2 expression .
|
-
- HY-100009
-
|
Flufenamic acid butyl ester; Butyl flufenamate
|
COX
Prostaglandin Receptor
|
Inflammation/Immunology
|
|
Ufenamate (Flufenamic acid butyl ester) is an anthranilic acid-based anti-inflammatory drug that can be used in the study of skin diseases such as acute and chronic eczema, contact dermatitis, diaper dermatitis, miliary rashes and atopic dermatitis. Ufenamate has a certain photoprotective effect, reduces the degree of skin erythema and swelling in the photoaging model, downregulates the expression level of COX-2 and can promote the healing of mouse skull defects by secreting BMP2 .
|
-
- HY-P1252A
-
|
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
|
Parathyroid Hormone (1-34), bovine TFA is a potent parathyroid hormone (PTH) receptor agonist. Parathyroid Hormone (1-34), bovine increases calcium and inorganic phosphate levels in vivo. Parathyroid Hormone (1-34), bovine can be used for th reseach of osteoporosis .
|
-
- HY-P1252
-
|
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
|
Parathyroid Hormone (1-34), bovine is a potent parathyroid hormone (PTH) receptor agonist. Parathyroid Hormone (1-34), bovine increases calcium and inorganic phosphate levels in vivo. Parathyroid Hormone (1-34), bovine can be used for th reseach of osteoporosis .
|
-
- HY-107818R
-
|
|
NF-κB
|
Cardiovascular Disease
Inflammation/Immunology
|
|
4-Hydroxychalcone (Standard) is the analytical standard of 4-Hydroxychalcone. This product is intended for research and analytical applications. 4-Hydroxychalcone is a chalcone metabolite with anti-angiogenic and anti-inflammatory activities. 4-Hydroxychalcone suppresses angiogenesis by suppression of growth factor pathway with no signs of cytotoxicity . 4-Hydroxychalcone inhibits TNF-α induced NF-κB pathway activation and activates BMP signaling, reduces resistant hypertension (RH) by attenuating hyperaldosteronism and renal injury in mice .
|
-
- HY-142042
-
|
|
MEK
TGF-beta/Smad
|
Neurological Disease
Inflammation/Immunology
Cancer
|
|
3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles is an inhibitor for bone morphogenetic protein 2 (BMP2) with an IC50 of 2.2 μM. 3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles is inhibitor for mitogen-activated protein kinase 1 (MEK1). 3-Hydroxy-4-carboxyalkylamidino-5-arylamino-isothiazoles exhibits anti-inflammatory and neuroprotective activity in EAE mouse model .
|
-
- HY-108464A
-
|
|
Sodium Channel
TRP Channel
|
Metabolic Disease
Inflammation/Immunology
|
|
Phenamil methanesulfonate, an analog of Amiloride (HY-B0285), is a more potent and less reversible epithelial sodium channel (ENaC) blocker with an IC50 of 400 nM . Phenamil methanesulfonate is also a competive inhibitor of TRPP3 and inhibits TRPP3-mediated Ca 2+ transport with an IC50 of 140 nM in a Ca 2+ uptake assay . Phenamil methanesulfonate is an intriguing small molecule to promote bone repair by strongly activating BMP signaling pathway . Phenamil methanesulfonate is used for the research of cystic fibrosis lung disease .
|
-
- HY-100434
-
|
|
FGFR
PDGFR
EGFR
Src
TGF-β Receptor
|
Cardiovascular Disease
Cancer
|
|
PD-161570 is a potent and ATP-competitive human FGF-1 receptor inhibitor with an IC50 of 39.9 nM and a Ki of 42 nM. PD-161570 also inhibits the PDGFR, EGFR and c-Src tyrosine kinases with IC50 values of 310 nM, 240 nM, and 44 nM, respectively. PD-161570 inhibits PDGF-stimulated autophosphorylation and FGF-1 receptor phosphorylation with IC50s of 450 nM and 622 nM, respectively . PD-161570 is also a bone morphogenetic proteins (BMPs) and TGF-β signaling inhibitor .
|
-
- HY-136848
-
|
|
MAP3K
Src
FGFR
Ribosomal S6 Kinase (RSK)
LIM Kinase (LIMK)
|
Cancer
|
|
SM1-71 (compound 5) is a potent TAK1 inhibitor, with a Ki of 160 nM, it also can covalently inhibit MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1 and RSK2. SM1-71 can inhibit proliferation of multiple cancer cell lines .
|
-
- HY-N0946
-
|
(-)-Pinoresinol 4-O-β-D-glucopyranoside
|
Glycosidase
|
Metabolic Disease
|
|
(-)-Pinoresinol 4-O-glucoside ((-)-Pinoresinol 4-O-β-D-glucopyranoside) is a potent and orally active α-glucosidase inhibitor with an IC50 value of 48.13 µM. (-)-Pinoresinol 4-O-glucoside increases cell migration and early differentiation of pre-osteoblasts. (-)-Pinoresinol 4-O-glucoside increases protein level of BMP2, p-Smad1/5/8, RUNX2. (-)-Pinoresinol 4-O-glucoside attenuates oxidative stress, hyperglycemia and hepatic toxicity. (-)-Pinoresinol 4-O-glucoside has the potential for the research of osteoporosis and periodontal disease .
|
-
- HY-173149
-
|
|
Anaplastic lymphoma kinase (ALK)
TGF-beta/Smad
TGF-β Receptor
|
Cancer
|
|
CDD-2789 is a highly selective small-molecule inhibitor targeting Activin receptor type 1 (ALK2, also known as ACVR1). It blocks the SMAD1/5 signaling pathway mediated by ALK2/ALK1, thereby effectively suppressing downstream phosphorylation events induced by BMP and activin A. In the NanoBRET cellular model, CDD-2789 exhibits an inhibitory IC50 of 0.54 µM against ALK2. CDD-2789 holds promise for research on ALK2-related diseases, including diffuse intrinsic pontine glioma (DIPG), ependymoma, endometrial cancer, melanoma, non–small cell lung cancer, colorectal cancer, and pancreatic cancer .
|
-
-
-
HY-L038
-
|
|
1,977 compounds
|
|
Stem cells, which are found in all multi-cellular organisms, can divide and differentiate into diverse special cell types and can self-renew to produce more stem cells. To be useful in therapy, stem cells must be converted into desired cell types as necessary which is called induced differentiation or directed differentiation. Understanding and using signaling pathways for differentiation is an important method in successful regenerative medicine. Small molecules or growth factors induce the conversion of stem cells into appropriate progenitor cells, which will later give rise to the desired cell type. There is a variety of signal molecules and molecular families that may affect the establishment of germ layers in vivo, such as fibroblast growth factors (FGFs); the wnt family or superfamily of transforming growth factors β (TGFβ) and bone morphogenetic proteins (BMP). Unfortunately, for now, a high cost of recombinant factors is likely to limit their use on a larger scale in medicine. The more promising technique focuses on the use of small molecules. These small molecules can be used for either activating or deactivating specific signaling pathways. They enhance reprogramming efficiency by creating cells that are compatible with the desired type of tissue. It is a cheaper and non-immunogenic method.
MCE Differentiation Inducing Compound Library contains a unique collection of 1,977 compounds that act on signaling pathways for differentiation. These compounds are potential stimulators for induced differentiation. This library is a useful tool for researching directed differentiation and regenerative medicine.
|
-
-
HY-L018
-
|
|
340 compounds
|
|
The transforming growth factor beta (TGF-β) signaling pathway is involved in many cellular processes in both the adult organism and the developing embryo including cell growth, cell differentiation, apoptosis, cellular homeostasis and other cellular functions. The TGF-β superfamily comprises TGF-βs, bone morphogenetic proteins (BMPs), activins and related proteins. Signaling begins with the binding of a TGF beta superfamily ligand to a TGF beta type II receptor. The type II receptor is a serine/threonine receptor kinase, which catalyzes the phosphorylation of the Type I receptor. The type I receptor then phosphorylates receptor-regulated SMADs (R-SMADs) which can now bind the coSMAD (e.g. SMAD4). R-SMAD/coSMAD complexes accumulate in the nucleus where they act as transcription factors and participate in the regulation of target gene expression. Deregulation of TGF-β signaling contributes to developmental defects and human diseases, including cancers, some bone diseases, chronic kidney disease, etc.
MCE designs a unique collection of 340 TGF-beta/Smad signaling pathway compounds. TGF-beta/Smad Compound Library acts as a useful tool for TGF-beta/Smad-related drug screening and disease research.
|
| Cat. No. |
Product Name |
Type |
-
- HY-12071G
-
|
DM-3189 (GMP)
|
Fluorescent Dye
|
|
LDN193189 (DM-3189) (GMP) is LDN193189 (HY-12071) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. LDN193189 is selective BMP type I receptor inhibitor .
|
-
- HY-12273G
-
|
|
Fluorescent Dye
|
|
DMH-1 (GMP) is a GMP-grade version of DMH-1 (HY-12273). Small molecules of GMP grade can be used as adjuvant reagents in cell therapy. DMH-1 (GMP) promotes cardiac differentiation in mouse embryonic stem cells. DMH-1 (GMP) promotes neurogenesis of hiPSCs. DMH-1 is a potent and selective BMP inhibitor .
|
| Cat. No. |
Product Name |
Type |
-
- HY-12071G
-
|
DM-3189 (GMP)
|
Biochemical Assay Reagents
|
|
LDN193189 (DM-3189) (GMP) is LDN193189 (HY-12071) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. LDN193189 is selective BMP type I receptor inhibitor .
|
-
- HY-167580
-
|
|
Drug Delivery
|
|
18:1 Hemi BMP (S,R) is a kind of biochemical reagent.
|
-
- HY-12273G
-
|
|
Biochemical Assay Reagents
|
|
DMH-1 (GMP) is a GMP-grade version of DMH-1 (HY-12273). Small molecules of GMP grade can be used as adjuvant reagents in cell therapy. DMH-1 (GMP) promotes cardiac differentiation in mouse embryonic stem cells. DMH-1 (GMP) promotes neurogenesis of hiPSCs. DMH-1 is a potent and selective BMP inhibitor .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P5832
-
|
|
Peptides
|
Others
|
|
BMP2-derived peptide is a functional motif from positions 73 to 92 of the amino acid sequence of BMP-2. BMP2-derived peptide promotes osteogenic differentiation of bone marrow stromal cells (BMSCs) and enhances bone regeneration .
|
-
- HY-107245
-
|
|
Estrogen Receptor/ERR
Sirtuin
RUNX
|
Metabolic Disease
|
|
Segetalin B, an orally active cyclopentapeptide found in Vaccaria segetalis, possesses estrogen-like activity. Segetalin B promotes mineralization of ovariectomized rat-derived bone marrow mesenchymal stem cells (BMSCs) in vitro and increases the level of osteocalcin, BMP-2, ALP, and SIRT1 activity. Segetalin B is promising for research of post-menopausal osteoporosis (PMOP) .
|
-
- HY-P0254A
-
|
|
Kisspeptin Receptor
|
Cardiovascular Disease
Cancer
|
|
Kisspeptin-10, human TFA is a potent vasoconstrictor and inhibitor of angiogenesis. Kisspeptin-10, human TFA acts as a tumor metastasis suppressor via its receptor GPR54. Kisspeptin-10-GPR54 system plays an important role in embryonic kidney development. Kisspeptin-10/GPR54 signaling induces osteoblast differentiation via NFATc4-mediated BMP2 expression .
|
-
- HY-P0254
-
|
|
Kisspeptin Receptor
|
Cardiovascular Disease
Cancer
|
|
Kisspeptin-10, human is a potent vasoconstrictor and inhibitor of angiogenesis. Kisspeptin-10, human acts as a tumor metastasis suppressor via its receptor GPR54. Kisspeptin-10-GPR54 system plays an important role in embryonic kidney development. Kisspeptin-10/GPR54 signaling induces osteoblast differentiation via NFATc4-mediated BMP2 expression .
|
-
- HY-P1252
-
|
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
|
Parathyroid Hormone (1-34), bovine is a potent parathyroid hormone (PTH) receptor agonist. Parathyroid Hormone (1-34), bovine increases calcium and inorganic phosphate levels in vivo. Parathyroid Hormone (1-34), bovine can be used for th reseach of osteoporosis .
|
-
- HY-P10710
-
|
|
IFNAR
Interleukin Related
COX
|
Inflammation/Immunology
|
|
BMP-4 is a penetrating heparin-binding peptide with anti-inflammatory and anti-chondrogenic functions. In murine chondrocytes and macrophages, BMP-4 regulates the iNOS-IFN-IL6 signaling pathway to inhibit the expression of inflammatory proteins such as iNOS, COX2, IFN, and IL6 in a dose-dependent manner, effectively suppressing inflammation and alleviating various arthritis symptoms .
|
-
- HY-P5457
-
|
|
Peptides
|
Others
|
|
BMP-2 Epitope (73-92) is a biological active peptide. (This is amino acids 73 to 92 fragment of bone morphogenetic protein (BMP) knuckle epitope. It is a member of transforming growth factor beta (TGF-b). This peptide fragment is able to raise alkaline phosphate activity in murine multipotent mesenchymal cells.)
|
-
- HY-P5157
-
|
|
Potassium Channel
|
Neurological Disease
|
|
BmP02 is a selective Kv1.3 channel blocker and a highly-selective Kv4.2 modulator, which can be isolated from Chinese scorpion (Buthus martensi Karsch) venom. BmP02 also delays the inactivation of Kv4.2 in HEK293T cells, with an EC50 value of ~850 nM. BmP02 inhibits the transient outward potassium currents (Ito) in ventricular muscle cells .
|
-
- HY-P1252A
-
|
|
Thyroid Hormone Receptor
|
Metabolic Disease
|
|
Parathyroid Hormone (1-34), bovine TFA is a potent parathyroid hormone (PTH) receptor agonist. Parathyroid Hormone (1-34), bovine increases calcium and inorganic phosphate levels in vivo. Parathyroid Hormone (1-34), bovine can be used for th reseach of osteoporosis .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P99359
-
|
ABT-555; AE12-1Y-QL; Anti-RGMA Reference Antibody (elezanumab)
|
TGF-beta/Smad
|
Metabolic Disease
|
|
Elezanumab (ABT-555; AE12-1Y-QL) is a human monoclonal antibody that selectively targets repulsive guidance molecule A (RGMa). Elezanumab potently inhibited RGMa mediated BMP signalling via the SMAD1/5/8 pathway, with an IC50 around 97 pM. Elezanumab promotes neuroregeneration and neuroprotection in neuronal injury and demyelination models binds N-terminal RGMa, blocks BMP signaling and lacks RGMc cross-reactivity. elezanumab has neuroregenerative and neuroprotective activities without impact on iron metabolism .
|
-
- HY-P99643
-
|
UCB6114
|
Dan family
|
Cancer
|
|
Ginisortamab (UCB6114) is a fully human IgG4P anti Gremlin-1 monoclonal antibody, with mean IC50 values of 8.2 nM and 9 nM against human and mouse gremlin-1, respectivly. Ginisortamab inhibits gremlin-1 antagonism of BMP signaling pathways. Ginisortamab has the potential for the research of gastrointestinal (GI) tumors .
|
-
- HY-P990974
-
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-N4019
-
-
-
- HY-N0123
-
-
-
- HY-N8920
-
-
-
- HY-107245
-
-
-
- HY-N2375
-
-
-
- HY-N0265
-
-
-
- HY-N0123R
-
|
Barbaloin-A (Standard)
|
Quinones
Structural Classification
Liliaceae
Anthraquinones
Source classification
Phenols
Polyphenols
Aloe vera (L.) Burm. f.
Plants
|
Reference Standards
Wnt
|
|
Aloin (Standard) is the analytical standard of Aloin. This product is intended for research and analytical applications. Aloin (Aloin-A; Barbaloin-A) is a natural anti-tumor anthraquinone glycoside with iron chelating activity. Aloin induces the differentiation of MC3T3-E1 cells into osteoblasts through MAPK-mediated Wnt and Bmp signaling pathways. Alkaline phosphatase (ALP) is an early marker of osteoblast differentiation, and the activity of ALP is also enhanced by Aloin. Aloin also reduces brain edema, reduces blood-brain barrier disruption and improves cortical impact injuries. Aloin is used in research into osteoporosis and traumatic brain injury (TBI) .
|
-
-
- HY-N2682B
-
-
-
- HY-N8261
-
|
|
Structural Classification
Microorganisms
Antibiotics
Source classification
|
Bacterial
TGF-beta/Smad
|
|
Amicoumacin B can be produced by actinomycete, strain 04-5195 T.. Amicoumacin B increases the expression of bone morphogenetic protein 2 (BMP-2). Amicoumacin B has inhibitory effect against C. violaceum (MIC = 250 µg/mL). Amicoumacin B has quorum sensing inhibitory activity, and reduces the expression of the C. violaceum operons vioA, vioB, vioD, and vioE, but increases the expression of vioC .
|
-
-
- HY-N0265R
-
-
-
- HY-N0316
-
-
-
- HY-N0316R
-
-
-
- HY-107818
-
-
-
- HY-107818R
-
|
|
Structural Classification
Chalcones
Monophenols
Flavonoids
other families
Source classification
Phenols
Plants
|
NF-κB
|
|
4-Hydroxychalcone (Standard) is the analytical standard of 4-Hydroxychalcone. This product is intended for research and analytical applications. 4-Hydroxychalcone is a chalcone metabolite with anti-angiogenic and anti-inflammatory activities. 4-Hydroxychalcone suppresses angiogenesis by suppression of growth factor pathway with no signs of cytotoxicity . 4-Hydroxychalcone inhibits TNF-α induced NF-κB pathway activation and activates BMP signaling, reduces resistant hypertension (RH) by attenuating hyperaldosteronism and renal injury in mice .
|
-
-
- HY-N0946
-
|
(-)-Pinoresinol 4-O-β-D-glucopyranoside
|
Structural Classification
Artemisia selengensis Turcz. ex Bess.
Source classification
Plants
Compositae
Saccharides
Monosaccharides
|
Glycosidase
|
|
(-)-Pinoresinol 4-O-glucoside ((-)-Pinoresinol 4-O-β-D-glucopyranoside) is a potent and orally active α-glucosidase inhibitor with an IC50 value of 48.13 µM. (-)-Pinoresinol 4-O-glucoside increases cell migration and early differentiation of pre-osteoblasts. (-)-Pinoresinol 4-O-glucoside increases protein level of BMP2, p-Smad1/5/8, RUNX2. (-)-Pinoresinol 4-O-glucoside attenuates oxidative stress, hyperglycemia and hepatic toxicity. (-)-Pinoresinol 4-O-glucoside has the potential for the research of osteoporosis and periodontal disease .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-RS01533
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
BMP1 Human Pre-designed siRNA Set A contains three designed siRNAs for BMP1 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS28931
-
|
|
|
siRNAs
Rat Pre-designed siRNA Sets
|
|
Bmp8a Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmp8a gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS24417
-
|
|
|
siRNAs
Rat Pre-designed siRNA Sets
|
|
Bmp6 Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmp6 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS25609
-
|
|
|
siRNAs
Rat Pre-designed siRNA Sets
|
|
Bmp5 Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmp5 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS17049
-
|
|
|
siRNAs
Mouse Pre-designed siRNA Sets
|
|
Bmp7 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmp7 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS23493
-
|
|
|
siRNAs
Rat Pre-designed siRNA Sets
|
|
Bmp7 Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmp7 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS01535
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
BMP15 Human Pre-designed siRNA Set A contains three designed siRNAs for BMP15 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS17946
-
|
|
|
siRNAs
Mouse Pre-designed siRNA Sets
|
|
Bmp6 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmp6 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS19176
-
|
|
|
siRNAs
Mouse Pre-designed siRNA Sets
|
|
Bmp15 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmp15 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS01539
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
BMP4 Human Pre-designed siRNA Set A contains three designed siRNAs for BMP4 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS20696
-
|
|
|
siRNAs
Mouse Pre-designed siRNA Sets
|
|
Bmp3 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmp3 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS23061
-
|
|
|
siRNAs
Rat Pre-designed siRNA Sets
|
|
Bmp2 Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmp2 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS25665
-
|
|
|
siRNAs
Rat Pre-designed siRNA Sets
|
|
Bmp15 Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmp15 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS16511
-
|
|
|
siRNAs
Mouse Pre-designed siRNA Sets
|
|
Bmp4 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmp4 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS19175
-
|
|
|
siRNAs
Mouse Pre-designed siRNA Sets
|
|
Bmp10 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmp10 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS01536
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
BMP2 Human Pre-designed siRNA Set A contains three designed siRNAs for BMP2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS01538
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
BMP3 Human Pre-designed siRNA Set A contains three designed siRNAs for BMP3 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS24817
-
|
|
|
siRNAs
Rat Pre-designed siRNA Sets
|
|
Bmp1 Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmp1 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS01543
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
BMP8A Human Pre-designed siRNA Set A contains three designed siRNAs for BMP8A gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS16626
-
|
|
|
siRNAs
Mouse Pre-designed siRNA Sets
|
|
Bmp2 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmp2 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS01541
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
BMP6 Human Pre-designed siRNA Set A contains three designed siRNAs for BMP6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS01542
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
BMP7 Human Pre-designed siRNA Set A contains three designed siRNAs for BMP7 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS19119
-
|
|
|
siRNAs
Mouse Pre-designed siRNA Sets
|
|
Bmp5 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmp5 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS22407
-
|
|
|
siRNAs
Mouse Pre-designed siRNA Sets
|
|
Bmp8a Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmp8a gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS22943
-
|
|
|
siRNAs
Rat Pre-designed siRNA Sets
|
|
Bmp4 Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmp4 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS27207
-
|
|
|
siRNAs
Rat Pre-designed siRNA Sets
|
|
Bmp3 Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmp3 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS01540
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
BMP5 Human Pre-designed siRNA Set A contains three designed siRNAs for BMP5 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS25664
-
|
|
|
siRNAs
Rat Pre-designed siRNA Sets
|
|
Bmp10 Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmp10 gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS01534
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
BMP10 Human Pre-designed siRNA Set A contains three designed siRNAs for BMP10 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS18338
-
|
|
|
siRNAs
Mouse Pre-designed siRNA Sets
|
|
Bmp1 Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmp1 gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS17130
-
|
|
|
siRNAs
Mouse Pre-designed siRNA Sets
|
|
Bmp2k Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmp2k gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS01537
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
BMP2K Human Pre-designed siRNA Set A contains three designed siRNAs for BMP2K gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS27380
-
|
|
|
siRNAs
Rat Pre-designed siRNA Sets
|
|
Bmp8b Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmp8b gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS01544
-
|
|
|
siRNAs
Human Pre-designed siRNA Sets
|
|
BMP8B Human Pre-designed siRNA Set A contains three designed siRNAs for BMP8B gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS20865
-
|
|
|
siRNAs
Mouse Pre-designed siRNA Sets
|
|
Bmp8b Mouse Pre-designed siRNA Set A contains three designed siRNAs for Bmp8b gene (Mouse), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
-
- HY-RS23575
-
|
|
|
siRNAs
Rat Pre-designed siRNA Sets
|
|
Bmp2k Rat Pre-designed siRNA Set A contains three designed siRNAs for Bmp2k gene (Rat), as well as a negative control, a positive control, and a FAM-labeled negative control.
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
